Loading company…
PROTEINA develops DNA-based diagnostics for profiling protein interactions and cancer signaling pathways.
Founded in 2015 and based in Seoul, PROTEINA develops Protein-Protein Interaction Profiling technology using single-molecule pull-down and co-immunoprecipitation methods. Its approach captures interactions between target and probe proteins to assess cancer signaling pathway activation. In October 2025, LB Investment sold 524,961 shares for approximately KRW 14.94 billion and retained a 4.42% stake.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in